NAS:EXEL (USA) Also trade in: Germany UK

Exelixis Inc

$ 20.87 -0.28 (-1.3%)
Volume: 1,256,788 Avg Vol (1m): 3,000,236
Market Cap $: 6.33 Bil Enterprise Value $: 5.53 Bil
P/E (TTM): 10.08 P/B: 4.77
Earnings Power Value -20.61
Net Current Asset Value 2.51
Tangible Book 4.16
Projected FCF 6.45
Median P/S Value 27.73
Graham Number 13.94
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked lower than
53.80% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
EXEL: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.21, Med: 1.5, Max: 10000
Current: 10000
0.21
10000
Equity-to-Asset 0.90
Equity-to-Asset ranked higher than
77.20% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
EXEL: 0.9
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.76, Med: 0.17, Max: 0.91
Current: 0.9
-0.76
0.91
Interest Coverage No Debt
Interest Coverage ranked lower than
74.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
EXEL: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 6.13, Med: 19.11, Max: 10000
Current: 10000
6.13
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 26.05
DISTRESS
GREY
SAFE
Beneish M-Score -1.52
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 155.93%
WACC 12.63%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 47.58
Operating Margin ranked higher than
96.46% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
EXEL: 47.58
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -863.61, Med: -56.02, Max: 51.4
Current: 47.58
-863.61
51.4
Net Margin % 75.97
Net Margin ranked higher than
96.09% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
EXEL: 75.97
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1040.57, Med: -69.5, Max: 80.82
Current: 75.97
-1040.57
80.82
ROE % 64.57
ROE ranked higher than
98.58% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
EXEL: 64.57
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -134.98, Med: 2.97, Max: 87.77
Current: 64.57
-134.98
87.77
ROA % 57.27
ROA ranked higher than
98.34% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
EXEL: 57.27
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -63.23, Med: -26.36, Max: 66.43
Current: 57.27
-63.23
66.43
ROC (Joel Greenblatt) % 418.12
ROC (Joel Greenblatt) ranked higher than
97.59% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
EXEL: 418.12
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -6260.17, Med: -1022.25, Max: 1202.67
Current: 418.12
-6260.17
1202.67
3-Year Total Revenue Growth Rate 184.30
3-Year Revenue Growth Rate ranked higher than
96.01% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
EXEL: 148.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -61.3, Med: 6.1, Max: 148.5
Current: 148.5
-61.3
148.5

» EXEL's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:EXEL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare NAS:ASND NAS:ARRY TSE:4587 NAS:NKTR NAS:AMRN XAMS:GLPG SZSE:002007 NAS:BLUE SZSE:002252 XBRU:ARGX NAS:MRNA SZSE:300347 NAS:NBIX SZSE:000661 NAS:ALNY NAS:TECH HKSE:06160 BOM:532523 NAS:JAZZ HKSE:01530
Traded in other countries EX9.Germany 0IJO.UK
Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer as Cometriq and advanced renal cell carcinoma, or kidney cancer, as Cabometyx. Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.

Ratios

Current vs industry vs history
PE Ratio (TTM) 10.08
PE Ratio ranked higher than
65.32% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
EXEL: 10.08
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 7.53, Med: 15.72, Max: 253.33
Current: 10.08
7.53
253.33
Forward PE Ratio 21.79
Forward P/E ranked higher than
62.34% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
EXEL: 21.79
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 10.08
PE without NRI ranked higher than
65.02% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
EXEL: 10.08
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 7.53, Med: 15.72, Max: 253.33
Current: 10.08
7.53
253.33
Price-to-Owner-Earnings 9.35
Price-to-Owner-Earnings ranked higher than
53.79% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
EXEL: 9.35
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 4.09, Med: 44.56, Max: 465.42
Current: 9.35
4.09
465.42
PB Ratio 4.77
PB Ratio ranked lower than
73.18% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
EXEL: 4.77
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.53, Med: 8.82, Max: 316.67
Current: 4.77
2.53
316.67
PS Ratio 7.69
PS Ratio ranked higher than
54.96% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
EXEL: 7.69
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.64, Med: 10.13, Max: 47.25
Current: 7.69
1.64
47.25
Price-to-Free-Cash-Flow 13.88
Price-to-Free-Cash-Flow ranked higher than
56.58% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
EXEL: 13.88
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 3.33, Med: 28.88, Max: 68.15
Current: 13.88
3.33
68.15
Price-to-Operating-Cash-Flow 12.98
Price-to-Operating-Cash-Flow ranked higher than
52.86% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
EXEL: 12.98
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.28, Med: 26.42, Max: 60.42
Current: 12.98
3.28
60.42
EV-to-EBIT 13.33
EV-to-EBIT ranked higher than
57.47% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
EXEL: 13.33
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -173, Med: -3.8, Max: 206.9
Current: 13.33
-173
206.9
EV-to-EBITDA 12.92
EV-to-EBITDA ranked higher than
55.16% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
EXEL: 12.92
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -177.8, Med: -3.95, Max: 200.5
Current: 12.92
-177.8
200.5
EV-to-Revenue 6.48
EV-to-Revenue ranked higher than
60.18% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
EXEL: 6.48
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.8, Med: 9.35, Max: 51.6
Current: 6.48
1.8
51.6
Current Ratio 7.56
Current Ratio ranked higher than
64.99% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
EXEL: 7.56
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.84, Med: 2.46, Max: 9.35
Current: 7.56
0.84
9.35
Quick Ratio 7.48
Quick Ratio ranked higher than
64.90% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
EXEL: 7.48
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.84, Med: 2.46, Max: 9.35
Current: 7.48
0.84
9.35
Days Inventory 119.94
Days Inventory ranked higher than
51.56% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
EXEL: 119.94
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 114.25, Med: 199.99, Max: 471.76
Current: 119.94
114.25
471.76
Days Sales Outstanding 45.93
Days Sales Outstanding ranked lower than
69.61% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
EXEL: 45.93
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 21.16, Med: 62.36, Max: 77.1
Current: 45.93
21.16
77.1
Days Payable 126.13
Days Payable ranked higher than
82.09% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
EXEL: 126.13
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 126.13, Med: 482.78, Max: 3050.92
Current: 126.13
126.13
3050.92

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.50
3-Year Share Buyback Rate ranked lower than
53.79% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
EXEL: -9.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -204.5, Med: -11.7, Max: -1.4
Current: -9.5
-204.5
-1.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.04
Price-to-Tangible-Book ranked lower than
69.35% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
EXEL: 5.04
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.46, Med: 9.34, Max: 437.86
Current: 5.04
2.46
437.86
Price-to-Projected-FCF 3.25
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
95.34% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
EXEL: 3.25
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.2, Med: 5.74, Max: 33.11
Current: 3.25
3.2
33.11
Price-to-Median-PS-Value 0.76
Price-to-Median-PS-Value ranked lower than
50.44% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
EXEL: 0.76
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 0.99, Max: 3.54
Current: 0.76
0.2
3.54
Price-to-Graham-Number 1.51
Price-to-Graham-Number ranked lower than
54.50% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
EXEL: 1.51
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.38, Med: 3.06, Max: 22.19
Current: 1.51
1.38
22.19
Earnings Yield (Joel Greenblatt) % 7.51
Earnings Yield (Greenblatt) ranked higher than
89.82% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
EXEL: 7.51
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -74, Med: -9.95, Max: 17.1
Current: 7.51
-74
17.1

More Statistics

Revenue (TTM) (Mil) $ 855.59
EPS (TTM) $ 2.08
Beta 1.77
Volatility % 62.11
52-Week Range $ 13.42 - 25.31
Shares Outstanding (Mil) 135.56

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y